Influence of tips on development of hepatocellular carcinoma in cirrhosis
Louis Libbrecht, Geert Maleux, Chris Verslype, Frederik Nevens, Tania Roskams – 12 May 2005
Safety of short‐term administration of celecoxib in decompensated cirrhosis
Mical S. Campbell, George A. Makar – 12 May 2005
Reply:
Shruti Mehta, David Thomas, Mark Sulkowski – 6 May 2005
Antiretroviral therapy and liver fibrosis in HIV‐infected patients with chronic hepatitis C
Juan Macías, José A. Mira, Salvador Vergara, Juan A. Pineda – 2 May 2005
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine‐resistant mutants
Alfredo Marzano, Pietro Lampertico, Vincenzo Mazzaferro, Silvia Carenzi, Mauro Vigano, Raffaele Romito, Andrea Pulvirenti, Alessandro Franchello, Massimo Colombo, Mauro Salizzoni, Mario Rizzetto – 21 April 2005 – The combination of lamivudine and hepatitis B immunoglobulin (HBIG) reduces the risk of hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, the efficacy of this strategy and the need for combined therapy with adefovir dipivoxil (ADV) in patients who select lamivudine‐resistant strains (YMDD) before surgery is still unknown.
Improved rat liver preservation by hypothermic continuous machine perfusion using polysol, a new, enriched preservation solution
Maud Bessems, Benedict M. Doorschodt, Arlène K. van Vliet, Thomas M. van Gulik – 21 April 2005 – For experimental machine perfusion (MP) of the liver, the modified University of Wisconsin solution (UW‐G) is most often used. In our search for an enriched MP preservation solution, Polysol was developed. Polysol is enriched with various amino acids, vitamins, and other nutrients for the liver metabolism. The aim of this study was to compare Polysol with UW‐G for MP preservation of the liver. Rat livers were preserved during 24 hours with hypothermic MP using UW‐G (n = 5) or Polysol (n = 5).
Liver transplantation for severe hepatic graft‐versus‐host disease: An analysis of aggregate survival data
Neal R. Barshes, G. Douglas Myers, Dean Lee, Saul J. Karpen, Timothy C. Lee, Akash J. Patel, Milton Finegold, John A. Goss – 21 April 2005 – Graft‐versus‐host disease (GVHD) often occurs after bone marrow transplantation (BMT). GVHD may lead to cirrhosis or complete destruction of the bile ducts, and few effective treatment options exist for such cases. Orthotopic liver transplantation (OLT) has been described as an option, but to date the patient survival, graft survival, and GVHD recurrence rates after OLT have been unknown.
Management of hepatitis C virus infection in the setting of liver transplantation
Hector Rodriguez‐Luna, Hugo E. Vargas – 21 April 2005 – Key Points
An open, randomized, multicenter clinical trial of oral tacrolimus in liver allograft transplantation: A comparison of dual vs. triple drug therapy
Miguel García González, Carlos Pera Madrazo, Ángel Bernardos Rodríguez, Manuel Gómez Gutiérrez, J. Ignacio Herrero, José Mir Pallardó, Jorge Ortiz de Urbina, Pascual Parrilla Paricio – 21 April 2005 – Triple therapy combining an anticalcineurin agent, corticosteroids, and azathioprine (AZA) in liver transplantation has been frequently applied, particularly in Europe. Debates have arisen concerning the use of a third drug (AZA), mainly in patients receiving tacrolimus (TAC).
Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living‐donor liver transplantation
Ayano Inui, Tsuyoshi Sogo, Haruki Komatsu, Hiroshi Miyakawa, Tomoo Fujisawa – 21 April 2005 – Graft dysfunction mimicking autoimmune hepatitis rarely develops after liver transplantation for nonautoimmune disease. The mechanism(s) and causes of de novo autoimmune hepatitis are unknown. We examined autoantibodies serially in a patient with de novo autoimmune hepatitis and in patients without de novo autoimmune hepatitis after liver transplantation.